Menu
Search
Home > Courses > Strategies (and New Agents) for Antiretroviral Therapy of HIV-1 Disease

Strategies (and New Agents) for Antiretroviral Therapy of HIV-1 Disease

Strategies (and New Agents) for Antiretroviral Therapy of HIV-1 Disease
Sorry, this learning module is not available for mobile devices.
This video is available at the Physicians Research Network website.

Original Release Date: 3/27/2012
Review Date: 7/20/2012
Presenter
  • Roy M. Gulick, MD, MPH
    Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases
    Weill Medical College of Cornell University, New York, NY
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Understand the evolving recommendations for when to start antiretroviral therapy (ART) for HIV disease.
  2. Identify optimal initial ART regimens.
  3. Know strategies for treatment-experienced patients.
  4. Learn about new antiretroviral agents for the treatment of HIV disease.
Presenter Bio
Roy Gulick, MD, MPH
Dr. Gulick is Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Cornell Medicine, and Attending Physician at the New York Presbyterian Hospital in New York City. Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiretroviral agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN), sponsored by the U.S. National Institutes of Health. He also serves as the Co-Chair of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection, Chair of the NIH Office of AIDS Research Advisory Committee (OARAC), a Board Member of the International Antiviral Society-USA, and previously served as a Member and as Chairman of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA).
PRN Learning Modules